Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 26

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 26
---
 in the CSN Facility, CSN Participants warrant and undertake that they will not grant any liens, charges or encumbrances over their AstraZeneca DIs.

The CSN Operator agrees to pass on communications from AstraZeneca and act on CSN Participants’ instructions to exercise voting and other rights in relation to their underlying AstraZeneca Shares (provided that it is put in funds if it is required to make any payment) and to take all reasonable steps to treat CSN Participants, so far as possible, in the same way as a registered holder of AstraZeneca Shares, as described above for AstraZeneca DI holders.

The CSN Operator (directly or through its nominee, the CSN Nominee) is appointed as agent for the CSN Participants to give CREST or, if applicable, DTC instructions. Neither the CSN Operator nor the CSN Nominee is responsible for losses incurred from acts or omissions of the CREST or DTC member through whom messages are delivered into CREST or DTC on its behalf or arising from CREST or DTC. CSN Participants are required to indemnify the CSN Operator and the CSN Nominee for costs and liabilities which may arise if they require the CSN Operator and the CSN Nominee to give CREST or DTC instructions which cannot be completed for any reasons connected with the CSN Participant.

The CSN Operator may terminate a CSN Participant’s participation in the CSN Facility if the CSN Participant materially breaches the CSN Terms and Conditions, in which case the CSN Nominee will be instructed to transfer the underlying AstraZeneca DIs to a CREST account, or the underlying AstraZeneca Shares to a DTC participant account, nominated by the CSN Participant or, in the absence of either CREST or DTC account information, the CSN Nominee will be instructed to arrange for the CSN Participant to be placed directly on the Register.

CSN Participants may be required to provide information in relation to their underlying holdings of AstraZeneca DIs on the same basis as such information may be required from a holder of AstraZeneca Shares.

The CSN Terms and Conditions do not restrict a CSN Participant’s rights under the rules of the Financial Conduct Authority or the UK Financial Services Act 2012 and can be amended with AstraZeneca’s consent.

The CSN Terms and Conditions are annexed to this document.

**(ii)**

#### CSN Non-El